Jack Stover
About Jack Stover
Independent director since July 2025; age 71. Former CEO/CFO and audit chair across multiple public biopharma companies; B.A. in Accounting from Lehigh University and Certified Public Accountant (CPA) . Serves in Class II of PFSA’s classified board (term expires at second annual meeting) .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Interpace Biosciences (IDXG) | President, CEO, Director; earlier Interim CEO | Jun 2016–Nov 2020; Dec 2015–Jun 2016 | Former Audit Committee Chair (2005–2015); led transformation in molecular diagnostics |
| Antares Pharma | CEO, President, Director | 2004–2008 | Led specialty pharma operations; public company governance experience |
| Viatar CTC Solutions | Director, Audit Committee Chair | Jun 2016–Dec 2016 | Audit oversight and controls |
| PricewaterhouseCoopers (Coopers & Lybrand) | Partner (bioscience industry division) | Prior to operating roles | Deep audit/accounting expertise in life sciences |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Traws Pharma (TRAW; f/k/a ONTX) | Lead Independent Director; Audit Chair; Compensation Committee Member; Special Deal Committee Chair | Since Nov 2018 | Extensive committee leadership; capital markets and governance oversight |
| Stero Therapeutics (private) | Director | Since Feb 2024 | Private company board experience |
| PharmaCyte Biotech (PMBC) | Director; Audit Committee Chair | Aug 15, 2022–Nov 1, 2022 | Short tenure as audit chair |
Board Governance
- Board structure: 5 directors in three staggered classes; Stover is Class II (with Peter O’Rourke) whose term expires at the second annual meeting .
- Committee assignments: Nominating & Corporate Governance Committee Member (committee chaired by Peter O’Rourke; members O’Rourke, Jack Stover, Lauren Chung) .
- Audit and Compensation Committees: Composed of Lauren Chung (Audit Chair), Rajesh Asarpota, Peter O’Rourke; and Rajesh Asarpota (Comp Chair), Lauren Chung, Peter O’Rourke, respectively. Stover is not listed on these committees .
- Independence: S-1 states three independent directors are O’Rourke, Asarpota, and Chung ; however, the nominating committee disclosure says each member (including Stover) qualifies as independent for nominating committee membership, indicating an inconsistency to monitor .
- Lead Independent Director: Peter O’Rourke; presides over executive sessions and liaises with the Chair/CEO .
- Risk oversight: Board oversees risk management; audit committee reviews risk assessment and related party transactions .
Fixed Compensation
| Component | Amount/Terms | Period |
|---|---|---|
| Non-employee director cash fees | No cash director fees paid in 2024 (historical Profusa policy prior to becoming a public company) | |
| Equity awards to non-employee directors | No equity awards granted in 2024 (historical Profusa) |
Note: PFSA’s current public-company director compensation details (retainers, committee chair fees, equity grants) were not disclosed in the reviewed filings; historical disclosure indicates no fees/awards in 2024 as a private company .
Performance Compensation
| Performance Metric | Applied to Director Pay? | Details |
|---|---|---|
| Revenue growth, EBITDA, TSR, ESG | None disclosed for director compensation | No performance-linked director pay metrics disclosed in reviewed filings |
Other Directorships & Interlocks
| Company | Relationship to PFSA (Supplier/Customer/Competitor) | Interlock/Conflict Notes |
|---|---|---|
| Traws Pharma (TRAW) | No disclosed transactional link | Multiple leadership roles; monitor for any future transactions creating conflicts |
| Stero Therapeutics (private) | No disclosed link | Private board; no PFSA-related transactions disclosed |
| PharmaCyte Biotech (PMBC) | No disclosed link | Former brief audit chair; no PFSA-related transactions disclosed |
Expertise & Qualifications
- CPA; former PwC partner with bioscience audit focus .
- Public company CEO/CFO experience in life sciences; extensive audit chair tenure .
- Lead independent director experience; deep committee leadership at other public company boards .
Equity Ownership
| Metric | Jul 30, 2025 (Post-Closing) | Sep 22, 2025 (Record Date) | Oct 8, 2025 (As of) |
|---|---|---|---|
| Shares beneficially owned | 8,658,652 | 8,658,652 | 8,658,652 |
| Ownership % of outstanding | 23.1% | 19.0% | 20.7% |
| Ownership structure notes | Through NorthView Sponsor I, LLC; Stover is a manager and disclaims beneficial ownership except for pecuniary interest | Through NorthView Sponsor I, LLC; Stover disclaims beneficial ownership except for pecuniary interest | Through NorthView Sponsor I, LLC; Stover disclaims beneficial ownership except for pecuniary interest |
Shares outstanding reference: 32,788,877 (Jul 30, 2025), 40,859,307 (Sep 22, 2025), 41,759,307 (Oct 8, 2025) as noted in filings .
Governance Assessment
- Strengths:
- Deep audit and financial expertise; prior Audit Chair roles across multiple biopharma issuers strengthen PFSA’s governance bench .
- Active on PFSA’s Nominating & Corporate Governance Committee, contributing to board effectiveness, succession planning, and governance guidelines .
- Risks/RED FLAGS:
- Sponsor-linked ownership: Significant stake via NorthView Sponsor I, LLC (≥19–23% across 2025 dates); potential alignment but also influence/independence scrutiny. Stover is a manager of the sponsor and disclaims beneficial ownership except pecuniary interest .
- Independence inconsistency: S-1 lists independent directors as O’Rourke, Asarpota, and Chung, omitting Stover, yet nominating committee disclosure says members (including Stover) qualify as independent for that committee; this discrepancy warrants clarification and could affect investor confidence .
- Related party backdrop: Historical NorthView sponsor arrangements (administrative services, private placement warrants, promissory notes) and ongoing related party balances highlight the need for robust audit oversight of related party transactions post-merger .
- Capital structure dilution signals: PIPE/ELOC facilities approved in 2025 may materially dilute existing holders; while not director-specific, board oversight of financing terms and shareholder protections is crucial .
Additional context: Audit committee oversees related person transactions; maintenance of strict recusal protocols is prudent given sponsor ties .